159783-46-7

Basic information

• Product Name: RARECHEM AL BD 0919
• Synonyms: RARECHEM AL BD 0919;(3,5-Dichloro-4-pyridyl)methanol
• CAS NO: 159783-46-7
• Molecular Formula: C6H5Cl2NO
• Molecular Weight: 178.02
• Mol File: 159783-46-7.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 280.2±35.0 °C(Predicted)
• Appearance: /
• Density: 1.478±0.06 g/cm3(Predicted)
• PKA: 12.09±0.10(Predicted)
• CAS DataBase Reference: RARECHEM AL BD 0919(CAS DataBase Reference)
• NIST Chemistry Reference: RARECHEM AL BD 0919(159783-46-7)
• EPA Substance Registry System: RARECHEM AL BD 0919(159783-46-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 159783-46-7(Hazardous Substances Data)

Usage

General Description

RARECHEM AL BD 0919 is a chemical compound identified by its numerical code, with its specific composition and properties not provided in the description. Without further information, it is difficult to provide a detailed summary of RARECHEM AL BD 0919. However, it is likely that it is part of the Rare Chemicals collection, and may have applications in various industries such as pharmaceuticals, agriculture, materials science, or other fields where specialty chemicals are used. It is important to note that the specific characteristics, hazards, and potential uses of RARECHEM AL BD 0919 can only be determined with access to its detailed chemical profile and safety data sheet.

Upstream product

• 2457-47-8 3,5-dichloropyridine 
• 144-55-8 sodium hydrogencarbonate 
• 136590-83-5 3,5-dichloropyridine-4-carboxaldehyde 

Downstream Products

• 159783-45-6 4-(bromomethyl)-3,5-dichloropyridine 
• 1064677-00-4 N-(3,5-dichloro-4-chloromethyl-pyridin-2-yl)-N-methyl-acetamide 
• 1256561-13-3 4-(bromomethyl)-3,5-dichloropyridine hydrobromide 
• 264123-70-8 3,5-dichloro-4-(chloromethyl)pyridine 

Relevant articles and documents

Towards redox-switchable organocatalysts based on bidentate halogen bond donors

Redox-active bidentate halogen bond donors based on halopyridinium groups as halogen-bond donating units were synthesized and their structures were elucidated by X-ray diffraction analyses and DFT calculations.Viareversible twofold reduction, these dicationic species can be transformed to neutral compounds which should be much weaker Lewis acids. The corresponding electrochemical data were obtained, and CV as well as UV-vis and NMR techniques were also used to determine binding constants of these halogen bond donors to halides. While all titrations agree on the relative order of binding strengths (with chloride being bound strongest), there are marked deviations in the overall affinity constants which are discussed. In contrast to earlier azo-bridge analogues, the ethylene-linked variants presented herein do not oxidize halides, and thus the novel halogen bond donors could also be used as Lewis acidic organocatalysts in a halide abstraction benchmark reaction, yielding a performance similar to bis(haloimidazolium)-derived catalysts.

RORγ MODULATORS

The invention provides an RORγ receptor agonist comprising a compound of formula (I), wherein the variables are as defined herein. These compounds are analogous to known RORγ receptor antagonists. The invention further provides a method of activating -the nuclear receptor RORγ, comprising -contacting the RORγ with an effective amount or concentration of a compound of the invention; and a method of treating cancer in a patient, comprising administering to the patient an effective dose of a compound of the invention.

N-Arylsulfonyl Indolines as Retinoic Acid Receptor-Related Orphan Receptor γ (RORγ) Agonists

The nuclear retinoic acid receptor-related orphan receptor γ (RORγ; NR1F3) is a key regulator of inflammatory gene programs involved in T helper 17 (TH17) cell proliferation. As such, synthetic small-molecule repressors (inverse agonists) targeting RORγ have been extensively studied for their potential as therapeutic agents for various autoimmune diseases. Alternatively, enhancing TH17 cell proliferation through activation (agonism) of RORγ may boost an immune response, thereby offering a potentially new approach in cancer immunotherapy. Herein we describe the development of N-arylsulfonyl indolines as RORγ agonists. Structure–activity studies reveal a critical linker region in these molecules as the major determinant for agonism. Hydrogen/deuterium exchange coupled to mass spectrometry (HDX-MS) analysis of RORγ–ligand complexes help rationalize the observed results.